Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9054518 | 0.81 | HTR6 (0.50) | HDAC8LOXL2HRH3 | |
| SCHEMBL27557499 | 0.73 | SLC6A4 (0.50) | HRH3LTA4H | |
| SCHEMBL6099938 | 0.71 | LTA4H (0.49) | HDAC8HRH3HRH4CHRNA7LTA4H | |
| SCHEMBL7385487 | 0.71 | PARP1 (0.41) | LOXL2HRH3HRH4 | |
| SCHEMBL16738 | 0.71 | POLB (0.58) | HRH3LTA4H | |
| SCHEMBL3495180 | 0.71 | POLB (0.58) | HRH3LTA4H | |
| SCHEMBL17415 | 0.71 | POLB (0.58) | HRH3LTA4H | |
| SCHEMBL476312 | 0.70 | LOXL2 (0.53) | HDAC8LOXL2HRH3HRH4CHRNA7 | |
| SCHEMBL8201261 | 0.69 | POLB (0.56) | HRH3LTA4H | |
| Hydrochloric Acid SCHEMBL12078757 | 0.69 | POLB (0.56) | HRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| WO-2008000818-A1 | FLUORINATED INDOLEAMIDES USEFUL AS LIGANDS OF THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2008-01-03 | — | — | WO | disclosed |
| EP-1873150-A1 | Fluorinated indoleamides useful as ligands of the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2008-01-02 | — | — | EP | disclosed |
| EP-1841755-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2007-10-10 | — | — | EP | disclosed |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | disclosed |
| US-20070082905-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-TRIAZOLYMETHYL-PIPERAZINE COMPOUNDS AND METHODS OF USING SAME | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676843-A1 | Substituted indole ligands for the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2006-07-05 | — | — | EP | disclosed |
| CN-1255401-C | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| EP-1648881-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GlaxoSmithKline S.p.A. (IT) | 2006-04-26 | — | — | EP | disclosed |
| US-6924278-B2 | Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| WO-2005005411-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GLAXOSMITHKLINE S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| US-6407106-B1 | FOR THERAPY OF INFLAMMATORY DISTURBANCES OF THE GASTROINTESTINAL TRACT | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | NPSR1, NTSR2, NTSR1 | HDAC8 918/4885LOXL2 3457/4885HRH3 323/4885 |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | HDAC8 3218/4885LOXL2 251/4885HRH3 128/4885 |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | TAC3, TACR1, SSTR5 | HDAC8 2146/4885LOXL2 2553/4885HRH3 229/4885 |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | OGFRL1, OPRL1, ORMDL3 | HDAC8 3562/4885LOXL2 364/4885HRH3 119/4885 |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | TACR1, NPSR1, SSTR2 | HDAC8 2041/4885LOXL2 2098/4885HRH3 31/4885 |
| US-20070082905-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-TRIAZOLYMETHYL-PIPERAZINE COMPOUNDS AND METHODS OF USING SAME | NT5C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PNLIP | HDAC8 452/4885LOXL2 3718/4885HRH3 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.